Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A P Grigg

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Australian and New Zealand Journal of Medicine|June 5, 1998
Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective studyD M Thomas, J F Seymour, J Szer, et al.
Bone Marrow Transplantation|May 1, 2007
A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantationM A Slavin, A P Grigg, A P Schwarer, et al.
Blood|December 15, 1995
Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteersA P Grigg, A W Roberts, H Raunow, et al.
Annals of Hematology|November 8, 2006
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphomaD S Ritchie, J F Seymour, A P Grigg, et al.
The Journal of Clinical Endocrinology and Metabolism|July 13, 2006
Pamidronate reduces bone loss after allogeneic stem cell transplantationA P Grigg, P Shuttleworth, J Reynolds, et al.
Leukemia & Lymphoma|December 29, 2004
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabineA P Grigg, J Reynolds, A McQuillan, et al.
Leukemia & Lymphoma|July 16, 2005
Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature reviewA P Grigg, J Bashford, J F Seymour, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
Internal Medicine Journal|July 1, 2008
Antifungal prophylaxis in adult stem cell transplantation and haematological malignancyM A Slavin, C H Heath, K A Thursky, et al.
Blood|December 15, 1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]H G Klingemann, A P Grigg, K Wilkie-Boyd, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Australian and New Zealand Journal of Medicine|June 5, 1998
Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective studyD M Thomas, J F Seymour, J Szer, et al.
Bone Marrow Transplantation|May 1, 2007
A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantationM A Slavin, A P Grigg, A P Schwarer, et al.
Blood|December 15, 1995
Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteersA P Grigg, A W Roberts, H Raunow, et al.
Annals of Hematology|November 8, 2006
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphomaD S Ritchie, J F Seymour, A P Grigg, et al.
The Journal of Clinical Endocrinology and Metabolism|July 13, 2006
Pamidronate reduces bone loss after allogeneic stem cell transplantationA P Grigg, P Shuttleworth, J Reynolds, et al.
Leukemia & Lymphoma|December 29, 2004
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabineA P Grigg, J Reynolds, A McQuillan, et al.
Leukemia & Lymphoma|July 16, 2005
Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature reviewA P Grigg, J Bashford, J F Seymour, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
Internal Medicine Journal|July 1, 2008
Antifungal prophylaxis in adult stem cell transplantation and haematological malignancyM A Slavin, C H Heath, K A Thursky, et al.
Blood|December 15, 1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]H G Klingemann, A P Grigg, K Wilkie-Boyd, et al.
Pageof 8